Stanford University’s Innovative Medicines Accelerator (IMA) is accepting proposals that address two major challenges in drug development: identifying drug candidates and optimization towards clinical leads.
Stanford University’s Innovative Medicines Accelerator (IMA) is accepting proposals for projects that use a recent advance in human organ modeling to address the IMA’s goals of accelerating the prototyping of innovative medicines and vaccines.
The Innovative Medicines Accelerator (IMA) is accepting proposals that address two major challenges in drug development: identifying drug leads and optimizing drug prototypes.
The Innovative Medicines Accelerator seeks to accelerate the prototyping of innovative early-stage translational stem cell and gene therapies that address unmet clinical needs.
The Innovative Medicines Accelerator (IMA) is accepting proposals that address two major challenges in drug development: identifying drug leads and optimizing drug prototypes.
IMA is accepting proposals for projects that leverage a recent technological advance in human organ modeling to accelerate the prototyping of innovative medicines and vaccines and to enable hypothesis-driven studies on human subjects.
The IMA seeks to support research projects aimed at testing hypotheses in human subjects that, if validated, have the potential to pave the road to new medicines, vaccines and diagnostics or to enhanced clinical use of existing ones.
The IMA, CDCM and CCT, seek to accelerate the development of promising and innovative early-stage translational stem cell and gene therapies that fill unmet clinical needs.
